Literature DB >> 23146904

The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery.

J P H Chow1, R Y C Poon.   

Abstract

Inhibition of cyclin-dependent kinase 1 (CDK1) by phosphorylation is a key regulatory mechanism for both the unperturbed cell cycle and the DNA damage checkpoint. Although both WEE1 and MYT1 can phosphorylate CDK1, little is known about the contribution of MYT1. We found that in contrast to WEE1, MYT1 was not important for the normal cell cycle or checkpoint activation. Time-lapse microscopy indicated that MYT1 did, however, have a rate-determining role during checkpoint recovery. Depletion of MYT1 induced precocious mitotic entry when the checkpoint was abrogated with inhibitors of either CHK1 or WEE1, indicating that MYT1 contributes to checkpoint recovery independently of WEE1. The acceleration of checkpoint recovery in MYT1-depleted cells was due to a lowering of threshold for CDK1 activation. The kinase activity of MYT1 was high during checkpoint activation and reduced during checkpoint recovery. Importantly, although depletion of MYT1 alone did not affect long-term cell growth, it potentiated with DNA damage to inhibit cell growth in clonogenic survival and tumor xenograft models. These results reveal the functions of MYT1 in checkpoint recovery and highlight the potential of MYT1 as a target for anti-cancer therapies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23146904     DOI: 10.1038/onc.2012.504

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  22 in total

Review 1.  Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations.

Authors:  Natalie Y L Ngoi; Shannon N Westin; Timothy A Yap
Journal:  Curr Opin Oncol       Date:  2022-07-05       Impact factor: 3.915

Review 2.  PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.

Authors:  Linjie Luo; Khandan Keyomarsi
Journal:  Expert Opin Investig Drugs       Date:  2022-05-03       Impact factor: 6.498

3.  Synergistic inhibition of colon cancer cell growth by a combination of atorvastatin and phloretin.

Authors:  Mo Zhou; Jinkai Zheng; Jinfeng Bi; Xinye Wu; Jian Lyu; Kun Gao
Journal:  Oncol Lett       Date:  2017-11-23       Impact factor: 2.967

4.  Prognostic significance of G2/M arrest signaling pathway proteins in advanced non-small cell lung cancer patients.

Authors:  Jing Wang; Yuhai Zhang; Shudi Xu; Weijie Li; Zhangqin Chen; Zhe Wang; Xinpeng Han; Yiling Zhao; Shengqing Li
Journal:  Oncol Lett       Date:  2015-01-02       Impact factor: 2.967

5.  Clinical significance of MYT1L gene polymorphisms in Chinese patients with gastric cancer.

Authors:  Yangmei Zhang; Haixia Zhu; Xunlei Zhang; Dongying Gu; Xichang Zhou; Meilin Wang; Chunxiang Cao; Xiaojing Zhang; Xiaomin Wu; Weida Gong; Yongfei Tang; Jianwei Zhou; Cuiju Tang; Zhengdong Zhang; Jinfei Chen
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

6.  Prolonged mitotic arrest induced by Wee1 inhibition sensitizes breast cancer cells to paclitaxel.

Authors:  Cody W Lewis; Zhigang Jin; Dawn Macdonald; Wenya Wei; Xu Jing Qian; Won Shik Choi; Ruicen He; Xuejun Sun; Gordon Chan
Journal:  Oncotarget       Date:  2017-05-13

7.  Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells.

Authors:  Majid Momeny; Farima Moghaddaskho; Narges K Gortany; Hassan Yousefi; Zahra Sabourinejad; Ghazaleh Zarrinrad; Shahab Mirshahvaladi; Haniyeh Eyvani; Farinaz Barghi; Leila Ahmadinia; Mahmoud Ghazi-Khansari; Ahmad R Dehpour; Saeid Amanpour; Seyyed M Tavangar; Leila Dardaei; Amir H Emami; Kamran Alimoghaddam; Ardeshir Ghavamzadeh; Seyed H Ghaffari
Journal:  Sci Rep       Date:  2017-03-13       Impact factor: 4.379

8.  Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells.

Authors:  Majid Momeny; Zahra Sabourinejad; Ghazaleh Zarrinrad; Farima Moghaddaskho; Haniyeh Eyvani; Hassan Yousefi; Shahab Mirshahvaladi; Ensieh M Poursani; Farinaz Barghi; Arash Poursheikhani; Leila Dardaei; Davood Bashash; Mahmoud Ghazi-Khansari; Seyyed M Tavangar; Ahmad R Dehpour; Marjan Yaghmaie; Kamran Alimoghaddam; Ardeshir Ghavamzadeh; Seyed H Ghaffari
Journal:  Sci Rep       Date:  2017-04-06       Impact factor: 4.379

9.  The G2 checkpoint-a node-based molecular switch.

Authors:  Mark C de Gooijer; Arnout van den Top; Irena Bockaj; Jos H Beijnen; Thomas Würdinger; Olaf van Tellingen
Journal:  FEBS Open Bio       Date:  2017-03-04       Impact factor: 2.693

10.  Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis.

Authors:  Joyce P Y Mak; Wing Yu Man; Hoi Tang Ma; Randy Y C Poon
Journal:  Oncotarget       Date:  2014-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.